Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
March 04 2019 - 7:05AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced that the Company’s
fourth quarter 2018 financial results will be released on Thursday,
March 7, 2019. Company management will host a conference call on
Thursday, March 7, 2019 at 1:30 p.m. Pacific Time/ 4:30 p.m.
Eastern Time to discuss the financial results and other recent
corporate highlights.
The press release and live audio webcast can be accessed via the
Investor section of the Company’s website at www.calithera.com. The
conference call can be accessed by dialing (855) 783-2599
(domestic) or (631) 485-4877 (international) and refer to
conference ID 9577446. Please log in approximately 5-10 minutes
before the event to ensure a timely connection. The archived
webcast will remain available for replay on Calithera’s website for
30 days.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer and other life-threatening diseases by
discovering, developing, and commercializing novel small molecule
drugs that target tumor and immune cell metabolism. Calithera is
headquartered in South San Francisco, California. For more
information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the safety,
tolerability and efficacy of Calithera’s product candidates, the
overall advancement of Calithera’s product candidates in clinical
trials, the unmet need in the treatment of patients with advanced
disease, and Calithera’s plans to continue development of its
product candidates. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024